Covidien Sells One Peripheral Device While Touting Data On Another
This article was originally published in The Gray Sheet
Executive Summary
Covidien announced it is selling its Stellarex drug-coated angioplasty balloon platform to Spectranetics for $30 million ahead of its merger with Medtronic, which makes the IN.PACT Admiral drug-coated balloon. But the company still plans to bring a significant peripheral vascular device portfolio along with it when it joins Medtronic.
You may also be interested in...
US Approvals Analysis: Drug-Coated Balloon, Valve Tech Are July Highlights
July was a relatively light month for novel-device approvals by US FDA, but year-to-date volumes remain strong. Spotlighted devices include approval of a new drug-coated balloon and heart valve devices. Here's a roundup from Medtech Insight's Approval Tracker.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.